Globeflex Capital L P Maintains Stake in Juniper Pharmaceuticals, Inc. (JNP)
Globeflex Capital L P maintained its stake in Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,012 shares of the specialty pharmaceutical company’s stock at the close of the 2nd quarter. Globeflex Capital L P owned about 0.18% of Juniper Pharmaceuticals worth $101,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of JNP. AWM Investment Company Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $475,000. Renaissance Technologies LLC lifted its stake in shares of Juniper Pharmaceuticals by 21.7% in the 1st quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock worth $1,470,000 after acquiring an additional 55,200 shares during the period. KCG Holdings Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $112,000. Goldman Sachs Group Inc. acquired a new stake in shares of Juniper Pharmaceuticals in the 1st quarter worth approximately $100,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Juniper Pharmaceuticals by 2.3% in the 2nd quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock worth $211,000 after acquiring an additional 941 shares during the period. 36.20% of the stock is owned by institutional investors.
JNP has been the subject of a number of research analyst reports. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $31.00 to $34.00 in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Juniper Pharmaceuticals presently has an average rating of “Buy” and an average price target of $23.00.
Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) opened at 4.55 on Friday. Juniper Pharmaceuticals, Inc. has a 52 week low of $3.65 and a 52 week high of $6.40. The stock has a 50 day moving average of $4.56 and a 200-day moving average of $4.63. The firm has a market capitalization of $49.34 million, a price-to-earnings ratio of 5.88 and a beta of 0.22.
Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.10. The firm had revenue of $13.96 million during the quarter, compared to analysts’ expectations of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. Analysts expect that Juniper Pharmaceuticals, Inc. will post ($0.46) earnings per share for the current year.
Juniper Pharmaceuticals Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.